Status:
UNKNOWN
Indirect Endovenous Systemic Ozone for New Coronavirus Disease (COVID19) in Non-intubated Patients
Lead Sponsor:
Javier Hidalgo Tallón
Collaborating Sponsors:
Sociedad Española de Ozonoterapia
Conditions:
COVID
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Systemic medical ozone has proved to help in several viral diseases, chronic obstructive pulmonary disease and chronic inflammation process. The investigators are sure that its application to COVID-19...
Detailed Description
Due to the extreme world situation caused by COVID19 pandemic, the investigators consider unethical not to try any treatment option with a justified rationale. The investigators have explained that m...
Eligibility Criteria
Inclusion
- COVID19 virus detected in oro/nasopharynx
- mild ill according WHO numeric scale
- mild ill according Berlin criteria
- non intubated patients
- signed informed consent
Exclusion
- patients treated with systemic ozone in the last 6 months
- patients treated before with systemic ozone and referring any side effect
- glucose-6-phosphate-dehydrogenase deficit
- other severe concomitant disease apart from COVID19
- psychiatric disease specified in axis I of l Diagnostic and Statistical Manual of Mental Disorders, 5 edition, but major depression
- patients not capable of understanding the study methods and targets
- pregnant woman
Key Trial Info
Start Date :
July 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2020
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04359303
Start Date
July 1 2020
End Date
December 1 2020
Last Update
June 23 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
SEOT
Valencia, Spain, 46013